Evommune, Inc. (EVMN)
NYSE:EVMN
Want to see EVMN full AI Analyst Report?
Top Page
Evommune, Inc.
(NYSE:EVMN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$24.00
▼(-12.57% Downside)
Action:ReiteratedDate:04/14/26
The score is mainly constrained by weak financial performance driven by large ongoing losses and accelerating cash burn, despite a substantially improved balance sheet. Technicals are moderately supportive with price above key moving averages and positive MACD, while valuation is weak due to a negative P/E and no dividend. Positive corporate developments (encouraging clinical data and significant financing) provide an offset but do not fully mitigate execution and cash-burn risk.
Positive Factors
Validated clinical proof-of-concept for EVO301
Positive randomized Phase 2a proof-of-concept for EVO301 meaningfully de-risks the IL-18 inhibition program, validating mechanism and enabling a defined path into Phase 2b and additional indications. This raises the long-term commercial and partnership potential for the immunology franchise.
Negative Factors
Deepening operating cash burn
Sustained and growing negative operating and free cash flows indicate high ongoing cash consumption to fund clinical programs. Unless R&D spending declines or revenue scales materially, the company will remain dependent on additional financing, raising dilution and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Validated clinical proof-of-concept for EVO301
Positive randomized Phase 2a proof-of-concept for EVO301 meaningfully de-risks the IL-18 inhibition program, validating mechanism and enabling a defined path into Phase 2b and additional indications. This raises the long-term commercial and partnership potential for the immunology franchise.
Read all positive factors
Evommune, Inc. (EVMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$851.11M
Dividend YieldN/A
Average Volume (3M)935.27K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue20.69
Enterprise Value/Gross Profit23.16
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$52.00Price Target Upside89.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Evommune, Inc. Business Overview & Revenue Model
Company Description
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urti...
How the Company Makes Money
null...
Evommune, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 13.00M | 7.00M | 5.00M |
| Gross Profit | 11.61M | 5.71M | 4.00M |
| EBITDA | -79.68M | -65.49M | -32.99M |
| Net Income | -68.87M | -66.81M | -34.05M |
Balance Sheet | |||
| Total Assets | 224.95M | 76.06M | 82.25M |
| Cash, Cash Equivalents and Short-Term Investments | 149.20M | 72.04M | 79.08M |
| Total Debt | 2.06M | 193.31M | 150.63M |
| Total Liabilities | 19.38M | 220.29M | 159.96M |
| Stockholders Equity | 205.57M | -144.24M | -77.71M |
Cash Flow | |||
| Free Cash Flow | -76.68M | -58.28M | -30.09M |
| Operating Cash Flow | -76.44M | -58.20M | -29.97M |
| Investing Cash Flow | -115.31M | -3.99M | -48.43M |
| Financing Cash Flow | 220.76M | 49.42M | 63.75M |
Evommune, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.64B | -4.89 | -49.31% | ― | -7.61% | 17.32% | |
52 Neutral | $851.11M | -4.77 | 89.72% | ― | ― | ― | |
52 Neutral | $626.25M | -5.95 | -2626.38% | ― | 8.83% | -24.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $243.59M | -1.44 | -29.13% | ― | -51.43% | 20.51% | |
49 Neutral | $586.95M | -3.32 | -49.35% | ― | 105.00% | 24.14% | |
42 Neutral | $453.50M | -3.25 | -74.52% | ― | 7.16% | -1934.64% |
* Healthcare Sector Average
EVMN
Evommune, Inc.
23.63
3.40
16.81%
ALT
Altimmune
3.02
-2.01
-39.96%
ARCT
Arcturus Therapeutics
8.57
-2.67
-23.75%
OCGN
Ocugen
1.85
1.14
158.74%
VIR
Vir Biotechnology
10.18
4.55
80.82%
VALN
Valneva
5.17
-1.31
-20.19%
Evommune, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy
Positive
Apr 13, 2026
On April 13, 2026, Evommune hosted a webcast detailing the migraine treatment landscape and presenting MRGPRX2 inhibition, via its oral small-molecule candidate EVO756, as a novel approach to address neuroinflammatory and mast cell drivers of migr...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Evommune Reports Q4 2025 Results and Pipeline Progress
Positive
Mar 5, 2026
Evommune, Inc. reported its fourth quarter and full-year 2025 results on March 5, 2026, highlighting positive Phase 2a proof-of-concept data for its injectable IL-18 binding protein fusion protein EVO301 in moderate-to-severe atopic dermatitis, wi...
Business Operations and StrategyPrivate Placements and Financing
Evommune Announces $125 Million Private Placement Financing
Positive
Feb 13, 2026
On February 12, 2026, Evommune, Inc. entered into a securities purchase agreement to sell 4,494,279 shares of its common stock at $27.88 per share in a private placement to a select group of new and existing mutual funds and dedicated healthcare i...
Business Operations and StrategyProduct-Related Announcements
Evommune Advances EVO301 After Positive Phase 2a Results
Positive
Feb 10, 2026
On Feb. 10, 2026, Evommune reported positive top-line data from a randomized, double-blind, placebo-controlled Phase 2a trial of its long-acting fusion protein EVO301 in 70 adults with moderate-to-severe atopic dermatitis. The intravenous regimen ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.